Bevenopran clinical trials
Also written CB-5945 and ADL5945.
How each study uses bevenopran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2013 (4)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (7)
Studies
Open first, then newest update. How each study uses bevenopran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer PainCompletedPhase 2Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01275755Written as ADL5945 0.25 mg
- Safety Study of CB-5945 for the Treatment of Opioid-Induced ConstipationTerminatedPhase 3Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01696643Written as CB-5945
- The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced ConstipationTerminatedPhase 3Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01901341Written as CB-5945
- Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced ConstipationTerminatedPhase 3Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01901302Written as CB-5945
- Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced ConstipationTerminatedPhase 3Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01901328Written as CB-5945
- Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer PainCompletedPhase 2Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01207427Written as ADL5945 0.1 mg
- Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal ImpairmentTerminatedPhase 1Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT02508740Written as bevenopran
Codes
What other systems call bevenopran · ClinicalTrials.gg INT016846
- UNII (FDA) IC58Q2EHPJBEVENOPRANConfirmed FDA, Wikidata
- Wikidata Q25100535bevenopranConfirmed FDA, Wikidata
- NCI Thesaurus C169810BevenopranOne source FDA
- DrugBank DB12464One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | IC58Q2EHPJ | BEVENOPRAN | Confirmed FDA, Wikidata |
| Wikidata | Q25100535 | bevenopran | Confirmed FDA, Wikidata |
| NCI Thesaurus | C169810 | Bevenopran | One source FDA |
| DrugBank | DB12464 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.